Lucius Pharmaceuticals
International business
Aildenafil / Evidence

The product story, seen through the study map.

A product-focused index of the mapped preclinical and PK/PD evidence.

Conceptual neurovascular scientific plate related to this page
02 / aildenafil

A shorter path into the Evidence library, with the same source and data-mode rules.

Study atlas

Each study answers only the question it can support.

Model, observation and figure stay connected without erasing source boundaries.

Evidence-question ownership map Nine source-mapped records connect by hairlines to three research questions: tissue stress, administration time and brain exposure.source-mapped recordsresearch questionGlobal ischemia modelEdema directionAQP4 directionMCAO model2 / 6 / 24 hWindow narrative0.5 h peak<5% at 6 h1.24× brain / plasma AUCTissue stress3 recordsAdministration time3 recordsBrain exposure3 records
01MCAO PK/PD: brain exposure profileMCAOpk / pd02Global cerebral ischemia: edema and AQP4 direction-of-effectBilateral common carotid artery ligation modelpreclinical / in / vivo03MCAO treatment-window studyMiddle cerebral artery occlusion (MCAO)preclinical / in / vivo
01
Mapped studies

Three studies create the first evidence constellation.

Global cerebral ischemia, MCAO treatment window and MCAO PK/PD each answer a different question. They should not be collapsed into one efficacy claim.

Continue exploring
01One canvas. Three connected directions.An interactive, source-aware mechanism narrative across vascular response, neurovascular recovery and neuroprotection.02Safety information should be easy to find.Structured safety information from the current company source, with clear limits and a medical-information path.03A library built around provenance.Study summaries, source status and data modes for the current Aildenafil research baseline.